Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhep.2023.10.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulatory Role and Biomarker Potential of Gut Microbiota Metabolites in the Progression of Metabolic dysfunction-associated steatotic liver disease (MASLD) to Hepatocellular Carcinoma (HCC).
Clin Transl Gastroenterol
September 2025
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. It is now updated as metabolic dysfunction-associated steatotic liver disease (MASLD). The progression of MASLD to hepatocellular carcinoma (HCC) involves complex mechanisms, with the gut microbiota and its metabolites playing a pivotal role in this transformation through the "gut-liver axis.
View Article and Find Full Text PDFEvidence From a Systematic Review of Non-alcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD) Fueling Cardiovascular Risk.
Cureus
August 2025
Obstetrics and Gynecology, Private Clinic 'Yana Alexandr', Sana'a, YEM.
Non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is increasingly implicated as a key risk factor for cardiovascular disease (CVD). However, its independent contribution remains debated due to confounding metabolic factors and methodological heterogeneity. This review aims to synthesize evidence on the association between NAFLD/MASLD and cardiovascular outcomes, focusing on the influence of liver fibrosis and metabolic dysfunction.
View Article and Find Full Text PDFDeficiency of Ugcg in LSECs alleviates high-fat diet-induced MASLD.
Hepatol Commun
September 2025
State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
Background: Hepatic glycosphingolipid biosynthesis is implicated in insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD). While UDP-glucose ceramide glucosyltransferase (UGCG) serves as the rate-limiting enzyme in glycosphingolipid synthesis, its cell-specific roles in MASLD pathogenesis remain undefined. Our study investigates the mechanistic contribution of LSEC-expressed UGCG to high-fat diet (HFD)-induced insulin resistance and MASLD progression.
View Article and Find Full Text PDFMetabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.
Clin Exp Hepatol
June 2025
Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Poznan, Poland.
The number of patients whose chronic metabolic liver disease leads to the development of hepatocellular carcinoma (HCC) is increasing. In patients with non-alcoholic fatty liver disease (NAFLD), HCC can arise in both cirrhotic and non-cirrhotic livers. This complicates appropriate surveillance and causes HCC to be diagnosed at a more advanced stage.
View Article and Find Full Text PDFAssociation between metabolic associated fatty liver disease and HCC risk after SVR in HCV patients: A systematic review and meta-analysis.
Clin Exp Hepatol
June 2025
Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Aim Of The Study: Chronic hepatitis C (CHC) infection remains one of the most prevalent chronic liver disease worldwide. A sustained virological response (SVR) can be achieved at high rates for CHC patients receiving direct-acting antivirals (DAAs). However, even small subsets of patients achieving SVR still have a risk of developing hepatocellular carcinoma (HCC).
View Article and Find Full Text PDF